Research programme: DCM-associated-gene-1 - Larnax
Alternative Names: DCM-associated-gene-1 research programme - LarnaxLatest Information Update: 20 Jul 2004
At a glance
- Originator Larnax (CEASED)
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 31 Dec 2003 Discontinued - Preclinical for Congestive heart failure in Germany (unspecified route)
- 26 Aug 2003 This programme is still in active development
- 01 Apr 2003 MediGene's cardiac and metabolic disease programme has been spun off as a new company, Larnax GmbH